MARKET

CYTO

CYTO

Altamira Therapeutics Ltd
NASDAQ
1.440
-0.140
-8.86%
After Hours: 1.490 +0.05 +3.47% 16:04 04/24 EDT
OPEN
1.600
PREV CLOSE
1.580
HIGH
1.600
LOW
1.400
VOLUME
2.97M
TURNOVER
0
52 WEEK HIGH
28.40
52 WEEK LOW
1.380
MARKET CAP
3.23M
P/E (TTM)
-0.1539
1D
5D
1M
3M
1Y
5Y
Altamira reports publication of positive results from NASAR clinical trial with Bentrio
Altamira reports publication of positive results from NASAR clinical trial with Bentrio nasal spray in seasonal allergic rhinitis. Bentrio is a drug-free and preservative-free nasal spray designed to help protect against airborne allergens. Altamira expects sales to grow significantly from 2024 onwards.
Seeking Alpha · 14h ago
Altamira Therapeutics Announces Publication Of Results From Bentrio Trial In Seasonal Allergic Rhinitis In Peer Reviewed Journal
Detailed results from randomized controlled Bentrio trial in seasonal allergic rhinitis published in Allergy journal. Study met primary efficacy endpoint of improvement in nasal symptoms and quality of life. Study outcomes support plans for further international expansion of Bentrio in Europe and the U.S.
Benzinga · 16h ago
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
The results from the NASAR clinical trial with Bentrio nasal spray in seasonal allergic rhinitis were published in Allergy. Bentrio is a drug-free and preservative-free nasal spray designed to help protect against airborne allergens. Altamira is a company dedicated to developing and commercializing RNA delivery technology.
Barchart · 21h ago
Weekly Report: what happened at CYTO last week (0415-0419)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Adial Pharmaceuticals (NASDAQ:ADIL) stock rose 34.2% to $2.59 during Monday's pre-market session. NKGen Biotech and T2 Biosystems moved upwards. Vaxxinity stock declined by 61.3% during the session.
Benzinga · 2d ago
Altamira Therapeutics Announces 2024 Annual Meeting
TipRanks · 04/16 21:57
Weekly Report: what happened at CYTO last week (0408-0412)?
Weekly Report · 04/15 12:25
Altamira Therapeutics FY EPS $(16.47) Sales $284.47K Down From $330.37K YoY
Altamira Therapeutics reported quarterly losses of $16.47 per share. The company reported $284.47 thousand in sales this quarter. This is a 13.89 percent decrease over sales of $330.37 thousand from the same period last year. Altamira also reported a 97.38 percent increase in losses.
Benzinga · 04/10 13:21
More
About CYTO
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.

Webull offers Altamira Therapeutics Ltd stock information, including NASDAQ: CYTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYTO stock methods without spending real money on the virtual paper trading platform.